Summary
Small cell lung cancer (SCLC) is one of the deadliest forms of lung cancer. It makes up about 15% of all lung cancer cases and has a 5-year survival rate of only 7%. While newer treatments like immunotherapy have helped some patients, most still see only small benefits. New small cell lung cancer research published in Nature Communications may help change that.
Scientists studied more than 179,000 tumor samples across 24 cancer types. They found that SCLC has the highest levels of a protein called DNAPKcs (made by the gene PRKDC). This protein helps cancer cells repair their DNA through a pathway called NHEJ. The problem? When DNAPKcs is high, tumors are better at hiding from the immune system. Patients with high levels also had worse survival and weaker responses to immunotherapy.
The research team tested what happens when DNAPKcs is blocked. The results were exciting. Blocking this protein triggered the body’s natural immune alarm system, called cGAS/STING. This made the cancer cells more visible to the immune system. Tumors became more sensitive to immunotherapy, and another cancer-driving protein called MYC was also broken down.
This matters because MYC has long been considered “undruggable.” Finding a new way to lower MYC could open doors to better treatments. Several DNAPKcs blockers are already being tested in clinical trials.
For SCLC patients, this small cell lung cancer research offers real hope. Combining DNAPKcs blockers with immunotherapy may one day help more patients respond and live longer. While more studies are needed, this discovery is an important step toward turning a “cold” tumor into one the immune system can fight.
Source: Chakraborty et al., Nature Communications, 2026.
